ReviewBioMed research international2014
Aptamers as both drugs and drug-carriers.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Computable properties of selected monomeric acylphloroglucinols with anticancer and/or antimalarial activities and first-approximation docking study.Journal of molecular modeling · 2025Article
- Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.Molecular therapy. Nucleic acids · 2024Review
- APIPred: An XGBoost-Based Method for Predicting Aptamer-Protein Interactions.Journal of chemical information and modeling · 2024Article
- DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers · 2023Review
- Review
- Cell Surface Transporters and Novel Drug Developments.Frontiers in pharmacology · 2022Review
- Article
- Breast Cancer Aptamers: Current Sensing Targets, Available Aptamers, and Their Evaluation for Clinical Use in Diagnostics.Cancers · 2021Review
- AptaNet as a deep learning approach for aptamer-protein interaction prediction.Scientific reports · 2021Article
- Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting.Frontiers in pharmacology · 2021Article
- Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy.International journal of molecular sciences · 2020Review
- AS1411 aptamer-modified theranostic liposomes co-encapsulating manganese oxide nano-contrast agent and paclitaxel for MRI and therapy of cancer.RSC advances · 2019Article
- Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer.International journal of molecular sciences · 2019Review
- Novel insights into the role of aptamers in the fight against cancer.Journal of cancer research and clinical oncology · 2019Review
- Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity.Bioconjugate chemistry · 2019Review
- Nucleic Acid Aptamer: A Novel Potential Diagnostic and Therapeutic Tool for Leukemia.OncoTargets and therapy · 2019Review
- Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.Molecules (Basel, Switzerland) · 2018Review
- Aptamers Selected for Recognizing Amyloid β-Protein-A Case for Cautious Optimism.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers are short nucleic acid oligos. They may serve as both drugs and drug-carriers. Their use as diagnostic tools is also evident. They can be generated using various experimental, theoretical, and computational techniques. The systematic evolution of ligands by exponential enrichment which uses iterative screening of nucleic acid libraries is a popular experimental technique. Theory inspired methodology entropy-based seed-and-grow strategy that designs aptamer templates to bind specifically to targets is another one. Aptamers are predicted to be highly useful in producing general drugs and theranostic drugs occasionally for certain diseases like cancer, Alzheimer's disease, and so on. They bind to various targets like lipids, nucleic acids, proteins, small organic compounds, and even entire organisms. Aptamers may also serve as drug-carriers or nanoparticles helping drugs to get released in specific target regions. Due to better target specific physical binding properties aptamers cause less off-target toxicity effects. Therefore, search for aptamer based drugs, drug-carriers, and even diagnostic tools is expanding fast. The biophysical properties in relation to the target specific binding phenomena of aptamers, energetics behind the aptamer transport of drugs, and the consequent biological implications will be discussed. This review will open up avenues leading to novel drug discovery and drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.